Data protection Impressum

Oncology

Limula, Actival, and AirCurve have received funding from the FIT to advance groundbreaking solutions in cell therapy production, dental health, and tracheal intubation. Limula secured a CHF 500,000 Tech Growth loan, while Actival and AirCurve each received CHF 100,000 Tech Seed loans.

Western Switzerland healthcare start-ups Limula, Actival, and AirCurve secure FIT funding

16 December 2024

Lymphatica Medtech, a Lausanne-based clinical-stage company specializing in innovative treatments for lymphedema, has raised EUR 17.9 million in a Series B funding round.

Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment

15 October 2024

HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments to advance RNA-guided therapies for obesity and metabolic disorders.

HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery

17 September 2024

BioAlps, the life sciences cluster of Western Switzerland, offers a dynamic network, an innovative and supportive environment and direct access to the region's vibrant life sciences ecosystem.

BioAlps, Western Switzerland’s life sciences cluster

iOnctura has secured EUR 80 million in a Series B funding round to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.

iOnctura secures EUR 80 million Series B financing to advance cancer treatments

25 June 2024

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (May 2024)

28 May 2024

HeroSupport and Calico Biosystems join Tech4Eva, a six-month equity-free accelerator dedicated to advancing women’s health technologies globally.

HeroSupport and Calico Biosystems selected for the Tech4Eva accelerator program

15 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

Researchers at the EPFL have engineered lab-grown mini-colons that replicate the development of colorectal tumors with high fidelity.

EPFL scientists create lab-grown mini-colons to advance colorectal cancer research

29 April 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (March 2024)

26 March 2024

1 2 3 4 5 … 8